Health Care [ 8/12 ] | Pharmaceuticals [ 50/74 ]
NASDAQ | Common Stock
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins.
Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing.
The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others.
Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells.
The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers.
Akari Therapeutics, Plc is headquartered in Tampa, Florida.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 20, 26 | -9.72 Decreased by -2.36% | -2.80 Decreased by -247.19% |
| Nov 13, 25 | -0.20 Increased by +75.08% | -0.11 Decreased by -81.82% |
| Aug 13, 25 | -0.06 Increased by +92.75% | -0.11 Increased by +45.45% |
| Apr 15, 25 | -0.19 Decreased by N/A% | -1.00 Increased by +81.00% |
| Dec 6, 24 | -9.50 Decreased by N/A% | - |
| Sep 30, 24 | -0.80 Decreased by -903.13% | - |
| May 15, 24 | -0.83 Decreased by -934.38% | - |
| Oct 12, 23 | 0.00 Increased by +100.00% | -0.60 Increased by +100.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 26 | 0.00 Decreased by -100.00% | -14.46 M Decreased by -290.15% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 25 | 0.00 Decreased by N/A% | -5.30 M Decreased by -40.46% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 25 | 0.00 Decreased by N/A% | -6.40 M Decreased by -121.07% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -1.90 M Increased by +74.93% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 26.00 K Increased by +N/A% | -3.71 M Increased by +33.44% | Decreased by -14.25 K% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by N/A% | -3.77 M Increased by +8.84% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -2.90 M Decreased by -0.84% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -7.56 M Decreased by -88.95% | Decreased by N/A% Decreased by N/A% |